gsk1265744b
HIV-associated Lipodystrophy Syndrome
ViiV HealthcarePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HIV-associated Lipodystrophy Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Efavirenz Juan A. Arnaiz | Phase 4 | A |
Lamivudine Thomas Benfield | Phase 4 | BBB |
ZIDOVUDINE Kirby Institute | Phase 4 | BBB |
Abacavir Kirby Institute | Phase 4 | BBB |
PRAVASTATIN Kirby Institute | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →